Cancer-Killing Effect Of High Oral-Dose Vitamin C

In an overlooked study first published in 2008, for the first time, using a special liposomal form of oral-dose vitamin C, researchers in Britain demonstrated it is possible to achieve cancer-killing blood concentrations of this vitamin without undesirable side effects.

Heretofore, National Institutes of Health Researchers claimed the maximal concentration of vitamin C that can be achieved following oral intake is not sufficient to produce a cancer-killing effect. Now British researchers demonstrate they were able to achieve blood concentrations of vitamin C that were twice what was incorrectly reported to be maximal, and in the range of what is known to be selectively toxic to tumor cells, yet not harmful to healthy cells.

Studies with various forms of cancer show a 30-to-50 percent cancer cell-killing effect at the same blood concentration of vitamin C achieved in this study. For comparison, anti-cancer drugs are approved by the FDA if they achieve 50 percent tumor shrinkage.

Researchers Stephen Hickey and Hilary J. Roberts, long-time advocates of vitamin C therapy and authors of the book Ascorbate: The Science of Vitamin C, writing in the Journal of Nutritional & Environmental Medicine, believe even higher concentration of vitamin C can be achieved, up to three times what was once mistakenly believed to be maximal, with measured, repeated oral doses.

It was Linus Pauling, the two-time Nobel Prize winner, who first employed intravenous vitamin C to prolong the lives of terminal cancer patients. This was reported in 1978.

A year later Mayo Clinic researchers then followed with a study of their own, which utilized oral-dose vitamin C, and errantly dispelled the notion of using vitamin C to treat cancer. However, oral doses cannot achieve the same high blood concentration that intravenous vitamin C can produce.

Only recently has it come to light that the dismissal of vitamin C for cancer therapy was based upon oral-dose vitamin C, and subsequent studies found intravenous vitamin C has the potential to be used in cancer therapy. Some small pilot studies appear to be encouraging with the use of intravenous vitamin C therapy. Cancer researchers have recently called for a reconsideration of intravenous vitamin C therapy.

According to researchers Hickey and Roberts, repeated doses, and use of a special liposomal form of vitamin C that is absorbed in the gut and then into the liver before it is released into the blood stream, are key to making oral vitamin C therapy effective. Another important factor is to limit the consumption of carbohydrates (refined sugar) which impairs oral absorption of this vitamin.

Dr. John Ely, emeritus professor at the University of Washington, has also shown that Sugar depletes vitamin C from white blood cells and makes them sluggish. White blood cells are the very cells that attack tumor cells and destroy them.

The liposomal form of vitamin C employed in this study consists of 1-gram (1000 milligram) dose sachets of vitamin C powder encapsulated in lecithin (phosphatidylcholine), as supplied by Livon Laboratories of Henderson, Nevada.

A British laboratory (Biolab, London) that has conducted thousands of vitamin C assays over a 10-year period, confirms that 20-gram and 36-gram doses of oral vitamin C, as utilized by researchers Hickey and Roberts, achieved far higher blood concentration than had ever been measured previously. Repeated dosing rather than massive single-dose vitamin C averts side effects such as diarrhea.

The cancer cell-killing effect of vitamin C is realized by the transient production of hydrogen peroxide (H2O2) within connective tissues (not in blood), which then destroys tumor cells, and subsequently turns to harmless water (H2O), ensuring non-toxic therapy.

Reluctance by modern medical practitioners to offer vitamin C therapy to their cancer patients suggests the public will have to practice vitamin C therapy at home. This need not be a totally unguided experience, as there are instructive books available. Why this landmark study has been completely overlooked by the cancer community goes unexplained. The study was published in a journal catalogued by the National Library of Medicine (NLM), but articles from that journal cannot be accessed at the NLM website. When this report was submitted for publication, the publisher of the journal suddenly changed editors and the new editor attempted to scratch the report from its publication schedule altogether. Finally the report did get published, but suddenly the journal itself was discontinued and its articles no longer indexed by NLM. It appears an intentional effort was made to bury this study. An online abstract is provided at the Journal of Nutritional and Environmental Medicine website.

Dr. Cinque's comments: I have said before that I would not want to undergo high-dose Vitamin C therapy all the time. However, my mind is entirely open to the possibility that it could be useful in treatment and management of cancer. Keep in mind that we are not talking about a nutritional effect here. It is most definitely a matter of poisoning. However, compared to chemotherapy, it is extremely safe and pretty close to harmless. And even in terminal cancer cases, it might bide the individvual much precious time.

Liposomal Encapsulation Technology has been around since the 1970s, but it is just now finding practical application. The idea is to provide nutrients in a form that resists degradation in the gut, for instance by wrapping it in a phospholipid such as lecithin, which leading to more efficient absorption and utilization. For instance, VRP has begun offering Liposomal Glutathione as a way to get around the digestive cleavage of the peptide bonds in the gut. This is major breakthrough, and it makes all other forms of glutathione obsolete.................
http://www.1to1vitamins.com/news/2010/artl7947.html


Chrisb1.
Tweet